Why Drugs For Orphan Diseases And Cancers Rule the Roost

Posted On 10 Mar 2014
By :

In 2013, the Food and Drug Administration (FDA) approved 27 new drugs for marketing. Eight of these drugs are for orphan diseases, including six rare cancers. In fact, more than half of the 139 drugs approved by the FDA since 2009 are for orphan diseases and cancers. This disproportion is not solely the result of scientific breakthroughs; the economics of drug development and the business of health care delivery also play large roles.

Read the source article at The New England Journal of Medicine

About the Author

Leave a Reply